+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Hospital-Acquired Infection Diagnostics Market Size, Share & Industry Trends Analysis Report By Product, By Infection Type, By Application, By Test Type, By End User, By Regional Outlook and Forecast, 2022 - 2028

  • PDF Icon

    Report

  • 335 Pages
  • May 2022
  • Region: Global
  • Marqual IT Solutions Pvt. Ltd (KBV Research)
  • ID: 5615434
The Global Hospital-Acquired Infection Diagnostics Market size is expected to reach $5.6 billion by 2028, rising at a market growth of 7.8% CAGR during the forecast period.



Infections acquired in hospitals are associated with viral, bacterial, or fungal pathogens. Numerous infections can be obtained in clinical settings such as nursing homes, rehabilitation center, outpatient clinics, or other therapeutic settings. It can be acquired from an infected patient, the surrounding environment, or the facility's staff. All patients are at risk for infections acquired in the hospital.

People that had surgery, the children and the elderly, are more likely to get hospital-acquired infections. The most common infections are surgical-site infections, respiratory infections, urinary tract infections, gastrointestinal infections, cardiovascular system infections, bloodstream infections, and bone and joint infections. Hospital-acquired infections (HAIs) are a leading cause of death among hospitalized patients in both developed and emerging countries.

All across the world, the amount of surgical procedures conducted each year has been steadily increasing, and by the end of the decade, it is predicted to hit a new high. As the need for surgical instruments grows along with the number of surgical procedures performed, the risk of healthcare-associated infections is expected to rise. A growing understanding of the value of sterilized and disinfected medical tools and devices is expected to help drive demand for nosocomial infection control equipment. Other factors driving sales of hospital obtained infection control systems include the increased frequency of chronic diseases and advances in surgical equipment.

Many clinicians can identify a HAI (Hospital acquired infection) based just on appearance and symptoms. Inflammation and/or a rash at the infection site might also be signs. HAIs do not include infections that develop complex prior to the stay. However, any additional symptoms should be reported to the doctor during the stay. The treatment for various illnesses is determined by the type of infection. Antibiotics and bed rest are likely to be prescribed by the doctor. It will also remove any foreign devices like catheters as soon as it's medically necessary.

COVID-19 Impact Analysis


COVID-19 was labeled a pandemic and overall well-being crisis of international concern by the World Health Organization (WHO) on January 30, 2020. Around 210 countries have been affected by COVID-19. Governments around the world have imposed mandatory lockdowns and social distancing to prevent the healthcare system from collapsing. Projects and elective procedures have also been subjected to limits and restrictions by states. The roadblocks continue to impede the expansion of various industries, and the increased response to the rules has an impact on the industries. Lockdowns around the world have damaged the distribution, production, and retail networks.

Market Growth Factors


Increasing awareness among people and healthcare institutions


Except for bacterial spores from inanimate things, disinfection is a technique that destroys the majority or all pathogenic microorganisms. Wet pasteurization or liquid chemicals are used to accomplish it. Several factors have influenced disinfection efficiency, each of which might limit the process' efficacy. The use of disinfectants in healthcare facilities to protect people doing the medical process that exposes people to the virus is on the rise. During the COVID-19 pandemic, the need for surface disinfectants was huge and is expected to grow significantly in the coming years.

The growing number of the surgical procedure


The amount of surgical treatment has increased dramatically throughout the years. Every year, many main surgical procedures, are conducted all over the world. The increased incidence of obesity and other lifestyle disorders, the growing senior population, and the rising prevalence of spinal injuries and sports-related injuries are all contributing to the rising cases of surgical procedures. As the amount of surgical treatment performed grows, so does the demand for various surgical equipment and medical gadgets.

Marketing Restraining Factor:


Problems associated with the safety of reprocessed medical instruments


To save money and avoid waste, healthcare practitioners reprocess reusable medical devices. Surgical forceps, stethoscopes, and endoscopes are instances of reusable medical devices. Although, it has questions regarding the reprocessed devices' safety and functionality. Improper instrument cleaning and sterilization can lead to the retention of blood, tissue, and other biological waste in reusable devices, raising the risk of surgical-site infections (SSIs) in patients. Microbes may be able to resist disinfection or sterilization because of the debris, which could contribute to HAIs.

Product Outlook


Based on Product, the market is segmented into Reagents & Consumables and Instrument. The reagents and consumables segment acquired the highest revenue share in the hospital-acquired infection diagnostics market in 2021. This is due to low awareness and a higher incidence of hospital-caused infections in low and medium-income nations. Chemicals and biological agents are employed in laboratory testing to detect or quantify an analyte, or the substance being evaluated or assessed. Cost, stability, availability, cold- or cool-chain requirements, and the risks associated with each variety vary greatly. Consumables are objects that are only utilized once during a test and then discarded and consist of items like coverslips and microscope slides that are specific to the test. Other consumables, which include alcohol, bleach, and gloves, are used throughout all testing services and are categorized as generic laboratory consumables.

Infection Type Outlook


Based on Infection Type, the market is segmented into Urinary Tract Infections (UTI), Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, and Others. The hospital-acquired pneumonia segment garnered a significant revenue share in the hospital-acquired infection diagnostics market in 2021. Hospital-acquired pneumonia (HAP), also known as nosocomial pneumonia, is a lower respiratory infection that was not incubated when the patient was admitted to the hospital and manifests clinically 2 or more days later. Early-onset pneumonia should be considered community-acquired pneumonia.

Application Outlook


Based on Application, the market is segmented into Drug-Resistance Testing and Disease Testing. The drug-resistance testing segment garnered the highest revenue share in the hospital-acquired infection diagnostics market in 2021. This is because drug-resistance testing can be used to see if a drug-resistant virus was spread. When resistance test results are available, the initial regimen can be tweaked if necessary. It is due to the quick turnaround time, reduced cost, and greater sensitivity for detecting mixes of wild-type and resistant virus, genotypic testing is recommended over phenotypic testing.

Test Type Outlook


Based on Test Type, the market is segmented into Molecular Diagnostics, Immunoassay, and Urinalysis. The Immunoassay segment procured a significant revenue share in the hospital-acquired infection diagnostics market in 2021. This test type is in demand due to an increase in infectious diseases, cancer, and pandemic outbreaks. Immunoassay is a highly selective bio-analytical approach that uses an antibody or antigen as a bio-recognition agent to quantify the existence or concentration of analytes ranging from tiny molecules to macromolecules in a solution.

End User Outlook


Based on End User, the market is segmented into Hospital, Standalone Laboratories, and Others. The hospital segment garnered the highest revenue share in the hospital-acquired infection diagnostics market in 2021. It is owing to the outbreak of a pandemic and a massive influx of patients. With the growth of new types of disease and the frequency of contraction of hospital-acquired infection, the role of hospitals comes into greater significance and will always grow in a progressive manner.

Regional Outlook


Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America emerged as the leading region in the hospital-acquired infection diagnostics market with the largest revenue share in 2021. It is due to a rise in the older population and the use of modern diagnostic equipment. As an outcome of the growing emphasis on healthy lifestyles and disease prevention among consumers, the market in this region is characterized by increasing demand for and adoption of sterilization and disinfection goods and services. The rise in the elderly population in the future years, as well as the requirement for hospitals, contracted infection control to reduce the prevalence of HAIs, and the execution of favorable government initiatives and stringent sterilization & disinfection regulations, are all driving the hospital-acquired infection diagnostics market in the region.

The major strategies followed by the market participants are Product Launches. Based on the Analysis presented in the Cardinal matrix; Johnson & Johnson and Pfizer, Inc. are the forerunners in the Hospital-Acquired Infection Diagnostics Market. Companies such as Abbott, Becton, Dickinson and Company, Ecolab, Inc.  are some of the key innovators in the Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson, Abbott Laboratories, and Merck Group.

» Partnerships, Collaborations and Agreements:

  • Apr-2020: Bayer joined hands with OrigiMed, a leading precision medicine company. This collaboration aimed to emphasize developing a CDx-IVD for larotrectinib (Vitrakvi) for the Chinese market and commercialization and development for NGS-based companion diagnostics-in Vitro diagnostic (CDx-IVD) in the detection of NTRK gene fusions.
  • Feb-2020: Becton, Dickinson, and Company came into a partnership with Babson Diagnostics, a transformative diagnostic blood testing company. This partnership aimed to bring laboratory-quality, small-volume blood collection to retail pharmacies. The partnership is expected to show emerging health care patterns onto faster, less expensive laboratory testing in customer-friendly healthcare settings with more suitable locations and hours, along with rapid growth in the diagnostic testing market.

» Product Launches and Product Expansions:

  • Dec-2021: Hologic unveiled Panther Trax, a new high volume molecular testing platform. This product launch aimed to allow labs to enhance testing volumes without any additional staff. Panther Trax is the new inclusion to Hologic's Panther Scalable Solutions (PSS) portfolio of products for lab automation. The new platform is listed as a Class I medical device with the US Food and Drug Administration (FDA) and CE-marked for diagnostic usage in Europe.
  • Dec-2021: Becton, Dickinson, and Company expanded its product line of BD COR System. This product expansion aimed to comprise a new MX instrument for high-throughput infectious diseases testing. This new MX instrument and its test for sexually transmitted infections have been granted CE mark approval, as per the IVD directive 98/79/EC.
  • Oct-2021: Hologic unveiled the Novodiag system, a fully automated molecular diagnostic solution for on-demand testing of antimicrobial resistance and infectious diseases. This product launch aimed to allow many pathogens to be identified in a single sample, delivering a simple and quick way to pinpoint patients at higher risk with syndromic and targeted on-demand testing.
  • Jul-2021: Abbott introduced Panbio COVID-19 Antigen Self-Test, for detection of SARS-CoV-2 virus in children and adults with symptoms or without any symptoms. This product launch aimed to fasten up testing of symptomatic and asymptomatic individuals and contacts of confirmed coronavirus cases. Abbott is expected to provide numerous Panbio COVID-19 Rapid Antigen Tests accessible for self-use.
  • Apr-2020: Hologic released a new Aptima molecular assay. Aptima molecular assay is expected to run on the Panther system, the detection of SARS-CoV-2 virus, which leads to Covid-19. This product launch aimed to level up the testing capabilities in the US by integrating its manufacturing capacity for the new test with its current high-throughput molecular instruments throughout the country.

» Acquisitions and Mergers:

  • Dec-2021: Pfizer entered into an agreement to acquire Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. This acquisition aimed to match the capabilities and expertise in Immunology and Inflammation and develop potential therapies for patients with debilitating immuno-inflammatory diseases with a requirement for more effective treatment options.

» Approvals and Trials:

  • Dec-2021: Pfizer received approval from U.S. Food and Drug Administration (FDA) for emergency use of PAXLOVID. This approval aimed to treat mild-to-moderate COVID-19 in adults and pediatric patients with positive outcomes of direct SARS-CoV-2 viral testing, and patients that are at greater risk for progression to severe COVID-19, comprising death or hospitalization. The treatment consists of nirmatrelvir, a novel main protease (Mpro) inhibitor originating in Pfizer’s laboratories, which was notably created to block the activity of the SARS-CoV-2 Mpro, an enzyme that the coronavirus required to replicate.
  • Mar-2020: Abbott received a U.S. Food and Drug Administration (FDA) approval for Emergency Use Authorization (EUA). This approval aimed for companies to perform the molecular test for novel coronavirus (COVID-19). Abbott RealTime SARS-CoV-2 EUA tests are used on the company's m2000 RealTime System. Abbott is delivering 150,000 Abbott RealTime SARS-CoV EUA tests to current consumers in the U.S.
  • Mar-2020: Abbott received a U.S. Food and Drug Administration (FDA) approval for the ID NOW platform. ID NOW platform is small, lightweight (6.6 pounds) and portable (the size of a small toaster), and utilizes molecular technology, which is valued by clinicians and the scientific community for its greater level of accuracy. This approval aimed to run the test on the company's ID NOW platform, delivering quick outcomes in a broad range of healthcare settings like physicians' offices, urgent care clinics, and hospital emergency departments.

Scope of the Study


Market Segments Covered in the Report:


By Product

  • Reagents & Consumables
  • Instrument

By Infection Type

  • Urinary Tract Infections (UTI)
  • Hospital Acquired Pneumonia
  • Bloodstream Infections
  • Surgical Site Infections
  • Gastrointestinal Infections
  • Others

By Application

  • Drug-Resistance Testing
  • Disease Testing

By Test Type

  • Molecular Diagnostics
  • Immunoassay
  • Urinalysis

By End User

  • Hospital
  • Standalone Laboratories
  • Others

By Geography

  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Key Market Players


List of Companies Profiled in the Report:

  • Bayer AG (Bayer Schering Pharma AG)
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Ecolab, Inc.
  • Pfizer, Inc.
  • Steris PLC
  • Johnson & Johnson
  • Abbott Laboratories
  • Merck Group

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Frequently Asked Questions about the Global Hospital-Acquired Infection Diagnostics Market

What is the estimated value of the Global Hospital-Acquired Infection Diagnostics Market?

The Global Hospital-Acquired Infection Diagnostics Market was estimated to be valued at $3347 Million in 2021.

What is the growth rate of the Global Hospital-Acquired Infection Diagnostics Market?

The growth rate of the Global Hospital-Acquired Infection Diagnostics Market is 7.7%, with an estimated value of $5582 Million by 2028.

What is the forecasted size of the Global Hospital-Acquired Infection Diagnostics Market?

The Global Hospital-Acquired Infection Diagnostics Market is estimated to be worth $5582 Million by 2028.

Who are the key companies in the Global Hospital-Acquired Infection Diagnostics Market?

Key companies in the Global Hospital-Acquired Infection Diagnostics Market include Bayer AG (Bayer Schering Pharma AG), Danaher Corporation, Becton, Dickinson and Company, Hologic, Inc., Ecolab, Inc., Pfizer, Inc., Steris PLC, Johnson & Johnson and Merck Group.

Table of Contents

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Hospital-Acquired Infection Diagnostics Market, by Product
1.4.2 Global Hospital-Acquired Infection Diagnostics Market, by Infection Type
1.4.3 Global Hospital-Acquired Infection Diagnostics Market, by Application
1.4.4 Global Hospital-Acquired Infection Diagnostics Market, by Test Type
1.4.5 Global Hospital-Acquired Infection Diagnostics Market, by End User
1.4.6 Global Hospital-Acquired Infection Diagnostics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. Global Hospital-Acquired Infection Diagnostics Market by Product
4.1 Global Reagents & Consumables Market by Region
4.2 Global Instrument Market by Region
Chapter 5. Global Hospital-Acquired Infection Diagnostics Market by Infection Type
5.1 Global Urinary Tract Infections (UTI) Market by Region
5.2 Global Hospital Acquired Pneumonia Market by Region
5.3 Global Bloodstream Infections Market by Region
5.4 Global Surgical Site Infections Market by Region
5.5 Global Gastrointestinal Infections Market by Region
5.6 Global Others Market by Region
Chapter 6. Global Hospital-Acquired Infection Diagnostics Market by Application
6.1 Global Drug-Resistance Testing Market by Region
6.2 Global Disease Testing Market by Region
Chapter 7. Global Hospital-Acquired Infection Diagnostics Market by Test Type
7.1 Global Molecular Diagnostics Market by Region
7.2 Global Immunoassay Market by Region
7.3 Global Urinalysis Market by Region
Chapter 8. Global Hospital-Acquired Infection Diagnostics Market by End User
8.1 Global Hospital Market by Region
8.2 Global Standalone Laboratories Market by Region
8.3 Global Others Market by Region
Chapter 9. Global Hospital-Acquired Infection Diagnostics Market by Region
9.1 North America Hospital-Acquired Infection Diagnostics Market
9.1.1 North America Hospital-Acquired Infection Diagnostics Market by Product
9.1.1.1 North America Reagents & Consumables Market by Country
9.1.1.2 North America Instrument Market by Country
9.1.2 North America Hospital-Acquired Infection Diagnostics Market by Infection Type
9.1.2.1 North America Urinary Tract Infections (UTI) Market by Country
9.1.2.2 North America Hospital Acquired Pneumonia Market by Country
9.1.2.3 North America Bloodstream Infections Market by Country
9.1.2.4 North America Surgical Site Infections Market by Country
9.1.2.5 North America Gastrointestinal Infections Market by Country
9.1.2.6 North America Others Market by Country
9.1.3 North America Hospital-Acquired Infection Diagnostics Market by Application
9.1.3.1 North America Drug-Resistance Testing Market by Country
9.1.3.2 North America Disease Testing Market by Country
9.1.4 North America Hospital-Acquired Infection Diagnostics Market by Test Type
9.1.4.1 North America Molecular Diagnostics Market by Country
9.1.4.2 North America Immunoassay Market by Country
9.1.4.3 North America Urinalysis Market by Country
9.1.5 North America Hospital-Acquired Infection Diagnostics Market by End User
9.1.5.1 North America Hospital Market by Country
9.1.5.2 North America Standalone Laboratories Market by Country
9.1.5.3 North America Others Market by Country
9.1.6 North America Hospital-Acquired Infection Diagnostics Market by Country
9.1.6.1 US Hospital-Acquired Infection Diagnostics Market
9.1.6.1.1 US Hospital-Acquired Infection Diagnostics Market by Product
9.1.6.1.2 US Hospital-Acquired Infection Diagnostics Market by Infection Type
9.1.6.1.3 US Hospital-Acquired Infection Diagnostics Market by Application
9.1.6.1.4 US Hospital-Acquired Infection Diagnostics Market by Test Type
9.1.6.1.5 US Hospital-Acquired Infection Diagnostics Market by End User
9.1.6.2 Canada Hospital-Acquired Infection Diagnostics Market
9.1.6.2.1 Canada Hospital-Acquired Infection Diagnostics Market by Product
9.1.6.2.2 Canada Hospital-Acquired Infection Diagnostics Market by Infection Type
9.1.6.2.3 Canada Hospital-Acquired Infection Diagnostics Market by Application
9.1.6.2.4 Canada Hospital-Acquired Infection Diagnostics Market by Test Type
9.1.6.2.5 Canada Hospital-Acquired Infection Diagnostics Market by End User
9.1.6.3 Mexico Hospital-Acquired Infection Diagnostics Market
9.1.6.3.1 Mexico Hospital-Acquired Infection Diagnostics Market by Product
9.1.6.3.2 Mexico Hospital-Acquired Infection Diagnostics Market by Infection Type
9.1.6.3.3 Mexico Hospital-Acquired Infection Diagnostics Market by Application
9.1.6.3.4 Mexico Hospital-Acquired Infection Diagnostics Market by Test Type
9.1.6.3.5 Mexico Hospital-Acquired Infection Diagnostics Market by End User
9.1.6.4 Rest of North America Hospital-Acquired Infection Diagnostics Market
9.1.6.4.1 Rest of North America Hospital-Acquired Infection Diagnostics Market by Product
9.1.6.4.2 Rest of North America Hospital-Acquired Infection Diagnostics Market by Infection Type
9.1.6.4.3 Rest of North America Hospital-Acquired Infection Diagnostics Market by Application
9.1.6.4.4 Rest of North America Hospital-Acquired Infection Diagnostics Market by Test Type
9.1.6.4.5 Rest of North America Hospital-Acquired Infection Diagnostics Market by End User
9.2 Europe Hospital-Acquired Infection Diagnostics Market
9.2.1 Europe Hospital-Acquired Infection Diagnostics Market by Product
9.2.1.1 Europe Reagents & Consumables Market by Country
9.2.1.2 Europe Instrument Market by Country
9.2.2 Europe Hospital-Acquired Infection Diagnostics Market by Infection Type
9.2.2.1 Europe Urinary Tract Infections (UTI) Market by Country
9.2.2.2 Europe Hospital Acquired Pneumonia Market by Country
9.2.2.3 Europe Bloodstream Infections Market by Country
9.2.2.4 Europe Surgical Site Infections Market by Country
9.2.2.5 Europe Gastrointestinal Infections Market by Country
9.2.2.6 Europe Others Market by Country
9.2.3 Europe Hospital-Acquired Infection Diagnostics Market by Application
9.2.3.1 Europe Drug-Resistance Testing Market by Country
9.2.3.2 Europe Disease Testing Market by Country
9.2.4 Europe Hospital-Acquired Infection Diagnostics Market by Test Type
9.2.4.1 Europe Molecular Diagnostics Market by Country
9.2.4.2 Europe Immunoassay Market by Country
9.2.4.3 Europe Urinalysis Market by Country
9.2.5 Europe Hospital-Acquired Infection Diagnostics Market by End User
9.2.5.1 Europe Hospital Market by Country
9.2.5.2 Europe Standalone Laboratories Market by Country
9.2.5.3 Europe Others Market by Country
9.2.6 Europe Hospital-Acquired Infection Diagnostics Market by Country
9.2.6.1 Germany Hospital-Acquired Infection Diagnostics Market
9.2.6.1.1 Germany Hospital-Acquired Infection Diagnostics Market by Product
9.2.6.1.2 Germany Hospital-Acquired Infection Diagnostics Market by Infection Type
9.2.6.1.3 Germany Hospital-Acquired Infection Diagnostics Market by Application
9.2.6.1.4 Germany Hospital-Acquired Infection Diagnostics Market by Test Type
9.2.6.1.5 Germany Hospital-Acquired Infection Diagnostics Market by End User
9.2.6.2 UK Hospital-Acquired Infection Diagnostics Market
9.2.6.2.1 UK Hospital-Acquired Infection Diagnostics Market by Product
9.2.6.2.2 UK Hospital-Acquired Infection Diagnostics Market by Infection Type
9.2.6.2.3 UK Hospital-Acquired Infection Diagnostics Market by Application
9.2.6.2.4 UK Hospital-Acquired Infection Diagnostics Market by Test Type
9.2.6.2.5 UK Hospital-Acquired Infection Diagnostics Market by End User
9.2.6.3 France Hospital-Acquired Infection Diagnostics Market
9.2.6.3.1 France Hospital-Acquired Infection Diagnostics Market by Product
9.2.6.3.2 France Hospital-Acquired Infection Diagnostics Market by Infection Type
9.2.6.3.3 France Hospital-Acquired Infection Diagnostics Market by Application
9.2.6.3.4 France Hospital-Acquired Infection Diagnostics Market by Test Type
9.2.6.3.5 France Hospital-Acquired Infection Diagnostics Market by End User
9.2.6.4 Russia Hospital-Acquired Infection Diagnostics Market
9.2.6.4.1 Russia Hospital-Acquired Infection Diagnostics Market by Product
9.2.6.4.2 Russia Hospital-Acquired Infection Diagnostics Market by Infection Type
9.2.6.4.3 Russia Hospital-Acquired Infection Diagnostics Market by Application
9.2.6.4.4 Russia Hospital-Acquired Infection Diagnostics Market by Test Type
9.2.6.4.5 Russia Hospital-Acquired Infection Diagnostics Market by End User
9.2.6.5 Spain Hospital-Acquired Infection Diagnostics Market
9.2.6.5.1 Spain Hospital-Acquired Infection Diagnostics Market by Product
9.2.6.5.2 Spain Hospital-Acquired Infection Diagnostics Market by Infection Type
9.2.6.5.3 Spain Hospital-Acquired Infection Diagnostics Market by Application
9.2.6.5.4 Spain Hospital-Acquired Infection Diagnostics Market by Test Type
9.2.6.5.5 Spain Hospital-Acquired Infection Diagnostics Market by End User
9.2.6.6 Italy Hospital-Acquired Infection Diagnostics Market
9.2.6.6.1 Italy Hospital-Acquired Infection Diagnostics Market by Product
9.2.6.6.2 Italy Hospital-Acquired Infection Diagnostics Market by Infection Type
9.2.6.6.3 Italy Hospital-Acquired Infection Diagnostics Market by Application
9.2.6.6.4 Italy Hospital-Acquired Infection Diagnostics Market by Test Type
9.2.6.6.5 Italy Hospital-Acquired Infection Diagnostics Market by End User
9.2.6.7 Rest of Europe Hospital-Acquired Infection Diagnostics Market
9.2.6.7.1 Rest of Europe Hospital-Acquired Infection Diagnostics Market by Product
9.2.6.7.2 Rest of Europe Hospital-Acquired Infection Diagnostics Market by Infection Type
9.2.6.7.3 Rest of Europe Hospital-Acquired Infection Diagnostics Market by Application
9.2.6.7.4 Rest of Europe Hospital-Acquired Infection Diagnostics Market by Test Type
9.2.6.7.5 Rest of Europe Hospital-Acquired Infection Diagnostics Market by End User
9.3 Asia Pacific Hospital-Acquired Infection Diagnostics Market
9.3.1 Asia Pacific Hospital-Acquired Infection Diagnostics Market by Product
9.3.1.1 Asia Pacific Reagents & Consumables Market by Country
9.3.1.2 Asia Pacific Instrument Market by Country
9.3.2 Asia Pacific Hospital-Acquired Infection Diagnostics Market by Infection Type
9.3.2.1 Asia Pacific Urinary Tract Infections (UTI) Market by Country
9.3.2.2 Asia Pacific Hospital Acquired Pneumonia Market by Country
9.3.2.3 Asia Pacific Bloodstream Infections Market by Country
9.3.2.4 Asia Pacific Surgical Site Infections Market by Country
9.3.2.5 Asia Pacific Gastrointestinal Infections Market by Country
9.3.2.6 Asia Pacific Others Market by Country
9.3.3 Asia Pacific Hospital-Acquired Infection Diagnostics Market by Application
9.3.3.1 Asia Pacific Drug-Resistance Testing Market by Country
9.3.3.2 Asia Pacific Disease Testing Market by Country
9.3.4 Asia Pacific Hospital-Acquired Infection Diagnostics Market by Test Type
9.3.4.1 Asia Pacific Molecular Diagnostics Market by Country
9.3.4.2 Asia Pacific Immunoassay Market by Country
9.3.4.3 Asia Pacific Urinalysis Market by Country
9.3.5 Asia Pacific Hospital-Acquired Infection Diagnostics Market by End User
9.3.5.1 Asia Pacific Hospital Market by Country
9.3.5.2 Asia Pacific Standalone Laboratories Market by Country
9.3.5.3 Asia Pacific Others Market by Country
9.3.6 Asia Pacific Hospital-Acquired Infection Diagnostics Market by Country
9.3.6.1 China Hospital-Acquired Infection Diagnostics Market
9.3.6.1.1 China Hospital-Acquired Infection Diagnostics Market by Product
9.3.6.1.2 China Hospital-Acquired Infection Diagnostics Market by Infection Type
9.3.6.1.3 China Hospital-Acquired Infection Diagnostics Market by Application
9.3.6.1.4 China Hospital-Acquired Infection Diagnostics Market by Test Type
9.3.6.1.5 China Hospital-Acquired Infection Diagnostics Market by End User
9.3.6.2 Japan Hospital-Acquired Infection Diagnostics Market
9.3.6.2.1 Japan Hospital-Acquired Infection Diagnostics Market by Product
9.3.6.2.2 Japan Hospital-Acquired Infection Diagnostics Market by Infection Type
9.3.6.2.3 Japan Hospital-Acquired Infection Diagnostics Market by Application
9.3.6.2.4 Japan Hospital-Acquired Infection Diagnostics Market by Test Type
9.3.6.2.5 Japan Hospital-Acquired Infection Diagnostics Market by End User
9.3.6.3 India Hospital-Acquired Infection Diagnostics Market
9.3.6.3.1 India Hospital-Acquired Infection Diagnostics Market by Product
9.3.6.3.2 India Hospital-Acquired Infection Diagnostics Market by Infection Type
9.3.6.3.3 India Hospital-Acquired Infection Diagnostics Market by Application
9.3.6.3.4 India Hospital-Acquired Infection Diagnostics Market by Test Type
9.3.6.3.5 India Hospital-Acquired Infection Diagnostics Market by End User
9.3.6.4 South Korea Hospital-Acquired Infection Diagnostics Market
9.3.6.4.1 South Korea Hospital-Acquired Infection Diagnostics Market by Product
9.3.6.4.2 South Korea Hospital-Acquired Infection Diagnostics Market by Infection Type
9.3.6.4.3 South Korea Hospital-Acquired Infection Diagnostics Market by Application
9.3.6.4.4 South Korea Hospital-Acquired Infection Diagnostics Market by Test Type
9.3.6.4.5 South Korea Hospital-Acquired Infection Diagnostics Market by End User
9.3.6.5 Singapore Hospital-Acquired Infection Diagnostics Market
9.3.6.5.1 Singapore Hospital-Acquired Infection Diagnostics Market by Product
9.3.6.5.2 Singapore Hospital-Acquired Infection Diagnostics Market by Infection Type
9.3.6.5.3 Singapore Hospital-Acquired Infection Diagnostics Market by Application
9.3.6.5.4 Singapore Hospital-Acquired Infection Diagnostics Market by Test Type
9.3.6.5.5 Singapore Hospital-Acquired Infection Diagnostics Market by End User
9.3.6.6 Malaysia Hospital-Acquired Infection Diagnostics Market
9.3.6.6.1 Malaysia Hospital-Acquired Infection Diagnostics Market by Product
9.3.6.6.2 Malaysia Hospital-Acquired Infection Diagnostics Market by Infection Type
9.3.6.6.3 Malaysia Hospital-Acquired Infection Diagnostics Market by Application
9.3.6.6.4 Malaysia Hospital-Acquired Infection Diagnostics Market by Test Type
9.3.6.6.5 Malaysia Hospital-Acquired Infection Diagnostics Market by End User
9.3.6.7 Rest of Asia Pacific Hospital-Acquired Infection Diagnostics Market
9.3.6.7.1 Rest of Asia Pacific Hospital-Acquired Infection Diagnostics Market by Product
9.3.6.7.2 Rest of Asia Pacific Hospital-Acquired Infection Diagnostics Market by Infection Type
9.3.6.7.3 Rest of Asia Pacific Hospital-Acquired Infection Diagnostics Market by Application
9.3.6.7.4 Rest of Asia Pacific Hospital-Acquired Infection Diagnostics Market by Test Type
9.3.6.7.5 Rest of Asia Pacific Hospital-Acquired Infection Diagnostics Market by End User
9.4 LAMEA Hospital-Acquired Infection Diagnostics Market
9.4.1 LAMEA Hospital-Acquired Infection Diagnostics Market by Product
9.4.1.1 LAMEA Reagents & Consumables Market by Country
9.4.1.2 LAMEA Instrument Market by Country
9.4.2 LAMEA Hospital-Acquired Infection Diagnostics Market by Infection Type
9.4.2.1 LAMEA Urinary Tract Infections (UTI) Market by Country
9.4.2.2 LAMEA Hospital Acquired Pneumonia Market by Country
9.4.2.3 LAMEA Bloodstream Infections Market by Country
9.4.2.4 LAMEA Surgical Site Infections Market by Country
9.4.2.5 LAMEA Gastrointestinal Infections Market by Country
9.4.2.6 LAMEA Others Market by Country
9.4.3 LAMEA Hospital-Acquired Infection Diagnostics Market by Application
9.4.3.1 LAMEA Drug-Resistance Testing Market by Country
9.4.3.2 LAMEA Disease Testing Market by Country
9.4.4 LAMEA Hospital-Acquired Infection Diagnostics Market by Test Type
9.4.4.1 LAMEA Molecular Diagnostics Market by Country
9.4.4.2 LAMEA Immunoassay Market by Country
9.4.4.3 LAMEA Urinalysis Market by Country
9.4.5 LAMEA Hospital-Acquired Infection Diagnostics Market by End User
9.4.5.1 LAMEA Hospital Market by Country
9.4.5.2 LAMEA Standalone Laboratories Market by Country
9.4.5.3 LAMEA Others Market by Country
9.4.6 LAMEA Hospital-Acquired Infection Diagnostics Market by Country
9.4.6.1 Brazil Hospital-Acquired Infection Diagnostics Market
9.4.6.1.1 Brazil Hospital-Acquired Infection Diagnostics Market by Product
9.4.6.1.2 Brazil Hospital-Acquired Infection Diagnostics Market by Infection Type
9.4.6.1.3 Brazil Hospital-Acquired Infection Diagnostics Market by Application
9.4.6.1.4 Brazil Hospital-Acquired Infection Diagnostics Market by Test Type
9.4.6.1.5 Brazil Hospital-Acquired Infection Diagnostics Market by End User
9.4.6.2 Argentina Hospital-Acquired Infection Diagnostics Market
9.4.6.2.1 Argentina Hospital-Acquired Infection Diagnostics Market by Product
9.4.6.2.2 Argentina Hospital-Acquired Infection Diagnostics Market by Infection Type
9.4.6.2.3 Argentina Hospital-Acquired Infection Diagnostics Market by Application
9.4.6.2.4 Argentina Hospital-Acquired Infection Diagnostics Market by Test Type
9.4.6.2.5 Argentina Hospital-Acquired Infection Diagnostics Market by End User
9.4.6.3 UAE Hospital-Acquired Infection Diagnostics Market
9.4.6.3.1 UAE Hospital-Acquired Infection Diagnostics Market by Product
9.4.6.3.2 UAE Hospital-Acquired Infection Diagnostics Market by Infection Type
9.4.6.3.3 UAE Hospital-Acquired Infection Diagnostics Market by Application
9.4.6.3.4 UAE Hospital-Acquired Infection Diagnostics Market by Test Type
9.4.6.3.5 UAE Hospital-Acquired Infection Diagnostics Market by End User
9.4.6.4 Saudi Arabia Hospital-Acquired Infection Diagnostics Market
9.4.6.4.1 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Product
9.4.6.4.2 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Infection Type
9.4.6.4.3 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Application
9.4.6.4.4 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by Test Type
9.4.6.4.5 Saudi Arabia Hospital-Acquired Infection Diagnostics Market by End User
9.4.6.5 South Africa Hospital-Acquired Infection Diagnostics Market
9.4.6.5.1 South Africa Hospital-Acquired Infection Diagnostics Market by Product
9.4.6.5.2 South Africa Hospital-Acquired Infection Diagnostics Market by Infection Type
9.4.6.5.3 South Africa Hospital-Acquired Infection Diagnostics Market by Application
9.4.6.5.4 South Africa Hospital-Acquired Infection Diagnostics Market by Test Type
9.4.6.5.5 South Africa Hospital-Acquired Infection Diagnostics Market by End User
9.4.6.6 Nigeria Hospital-Acquired Infection Diagnostics Market
9.4.6.6.1 Nigeria Hospital-Acquired Infection Diagnostics Market by Product
9.4.6.6.2 Nigeria Hospital-Acquired Infection Diagnostics Market by Infection Type
9.4.6.6.3 Nigeria Hospital-Acquired Infection Diagnostics Market by Application
9.4.6.6.4 Nigeria Hospital-Acquired Infection Diagnostics Market by Test Type
9.4.6.6.5 Nigeria Hospital-Acquired Infection Diagnostics Market by End User
9.4.6.7 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market
9.4.6.7.1 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Product
9.4.6.7.2 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Infection Type
9.4.6.7.3 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Application
9.4.6.7.4 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by Test Type
9.4.6.7.5 Rest of LAMEA Hospital-Acquired Infection Diagnostics Market by End User
Chapter 10. Company Profiles
10.1 Bayer AG (Bayer Schering Pharma AG)
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 Recent Strategies and Developments
10.1.5.1 Partnerships, Collaborations and Agreements
10.2 Danaher Corporation
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Segmental and Regional Analysis
10.2.4 Research & Development Expense
10.3 Becton, Dickinson and Company
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental and Regional Analysis
10.3.4 Research & Development Expense
10.3.1 Recent Strategies and Developments
10.3.1.1 Partnerships, Collaborations and Agreements
10.3.1.2 Product Launches and Product Expansions
10.4 Hologic, Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent Strategies and Developments
10.4.5.1 Partnerships, Collaborations and Agreements
10.4.5.2 Product Launches and Product Expansions
10.5 Ecolab, Inc.
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expenses
10.5.5 Recent Strategies and Developments
10.5.5.1 Product Launches and Product Expansions:
10.5.5.2 Geographical Expansions:
10.6 Pfizer, Inc.
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Regional & Segmental Analysis
10.6.4 Research & Development Expense
10.6.5 Recent Strategies and Developments
10.6.5.1 Approvals and Trials:
10.6.5.2 Acquisitions and Mergers
10.7 Steris PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expenses
10.8 Johnson & Johnson
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Segmental &Regional Analysis
10.8.4 Research & Development Expenses
10.9 Abbott Laboratories
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Segmental and Regional Analysis
10.9.4 Research & Development Expense
10.9.5 Recent Strategies and Developments
10.9.5.1 Approvals and Trials:
10.9.5.2 Product Launches and Product Expansions:
10.10. Merck Group
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expense
10.10.5 Recent Strategies and Developments
10.10.5.1 Partnerships, Collaborations and Agreements

Companies Mentioned

  • Bayer AG (Bayer Schering Pharma AG)
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Hologic, Inc.
  • Ecolab, Inc.
  • Pfizer, Inc.
  • Steris PLC
  • Johnson & Johnson
  • Abbott Laboratories
  • Merck Group

Methodology

Loading
LOADING...